Table 2 Patient and tumour factors and association with level of axillary nodal burden on pathology
No residual macrometastatic nodes n (%) | 1–2 residual metastatic nodes n (%) | More than 2 residual metastatic nodes n (%) | p-value | |
|---|---|---|---|---|
Total | 33 (37.9%) | 28 (32.2%) | 26 (29.9%) | |
Patient median age (years) | 50.0 | 48.5 | 53.0 | 0.319 |
Trastuzumab given | ||||
yes | 18 (53%) | 8(23.5%) | 8 (23.5%) | 0.068 |
no | 15 (28%) | 20 (38%) | 18 (34%) | |
Type of chemo | ||||
FEC | 2 (14%) | 7 (50%) | 5 (36%) | |
Taxane | 2 (40%) | 2 (40%) | 1 (20%) | 0.325 |
both | 29 (43%) | 19 (28%) | 20 (29%) | |
Tumour type | ||||
Ductal | 30 (38%) | 27 (34%) | 22 (28%) | 0.015 |
Lobular | 0 (0%) | 0 (0%) | 4 (100%) | |
Other | 3 (75%) | 1 (25%) | 0 (0%) | |
Tumour grade | ||||
1 | 0 (0%) | 1 (100%) | 0 (0%) | 0.080 |
2 | 6 (26%) | 12 (52%) | 5 (22%) | |
3 | 27 (43%) | 15 (24%) | 21 (33%) | |
T staging | ||||
T1 | 1 (100%) | 0 (0%) | 0 (0%) | 0.188 |
T2 | 21 (40%) | 21 (40%) | 11 (20%) | |
T3 | 7 (39%) | 3 (17%) | 8 (44%) | |
T4 | 4 (27%) | 4 (27%) | 7 (46%) | |
Immunophenotype | ||||
ER + ve/HER2 + ve | 13 (50%) | 8 (31%) | 5 (19%) | |
ER + ve/HER2 -ve | 6 (20%) | 15 (50%) | 9 (30%) | 0.044 |
ER -ve/HER2 + ve | 5 (63%) | 0 (0%) | 3 (37%) | |
ER -ve/HER2 –ve | 9 (39%) | 5 (22%) | 9 (39%) | |